Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
5.71
-0.15 (-2.56%)
At close: Feb 18, 2026, 4:00 PM EST
5.72
+0.01 (0.13%)
After-hours: Feb 18, 2026, 7:54 PM EST
Verastem Revenue
Verastem had revenue of $11.24M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $13.38M, up 33.79% year-over-year. In the year 2024, Verastem had annual revenue of $10.00M.
Revenue (ttm)
$13.38M
Revenue Growth
+33.79%
P/S Ratio
32.94
Revenue / Employee
$171,526
Employees
78
Market Cap
440.71M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 2.60M | 543.00K | 26.45% |
| Dec 31, 2021 | 2.05M | -86.46M | -97.68% |
| Dec 31, 2020 | 88.52M | 71.06M | 407.08% |
| Dec 31, 2019 | 17.46M | -9.26M | -34.67% |
| Dec 31, 2018 | 26.72M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Invivyd | 50.04M |
| Assembly Biosciences | 37.19M |
| Ocugen | 5.37M |
| Upstream Bio | 2.80M |
| vTv Therapeutics | 17.00K |
VSTM News
- 16 hours ago - Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Business Wire
- 14 days ago - Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers - Business Wire
- 5 weeks ago - Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 7 weeks ago - Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC - Seeking Alpha
- 7 weeks ago - Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer - Business Wire
- 2 months ago - Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth - Business Wire
- 3 months ago - Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference - Business Wire
- 3 months ago - Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants - Business Wire